Cite

HARVARD Citation

    Weiss, K. et al. (n.d.). O01 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial. Gut. p. A1. [Online]. 
  
Back to record